New Report Identifies Commercial Opportunities in Cancer Stem Cell Drug Discovery and Diagnostics

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which predicts that if key research is clinically confirmed, the selective targeting of Cancer Stem Cells (CSCs) will offer a new paradigm in cancer therapeutics, diagnostics and significant market opportunity.

(PRWEB) January 27, 2008 -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has now added a new report which predicts that if key research is clinically confirmed, the selective targeting of Cancer Stem Cells (CSCs) will offer a new paradigm in cancer therapeutics, diagnostics and significant market opportunity.

"Cancer Stem Cells -- Emerging Therapeutic, Diagnostic and Market Opportunities (2008)" which is available at http://www.piribo.com/publications/diseases_conditions/cancer/cancer_stem_cells.html finds that there are commercial opportunities in drug discovery and diagnostics relating to CSCs.

The report states that CSCs are causally linked to the development and metastatic spread of cancer and further research will likely place CSCs at the heart of cancer diagnostics. There are currently more than 30 CSC R&D programmes in progress. Around 50% of these are at Phase I or beyond. Patient data from the first clinical trials of drugs believed to target CSCs, are now being reported, it says.

Authors of the report say that substantial opportunity for collaboration is this field has recently lead to agreements between Small and Medium Enterprises (SMEs) and major pharmaceutical companies. This includes a recent announcement of a collaboration between GSK and Oncomed Pharmaceuticals, Inc.

The study identifies five "Top-25" pharmaceutical companies that are progressing developments relating to CSCs. It also includes the drug pipeline (pre-clinical to Phase III), discovery strategy, candidate molecules, drug targets, current clinical trials and related areas.

Analysts examine current developments on the detection of CSCs and new diagnostic approaches. More than 50 academic research teams from 13 different countries are reviewed, together with leading discoveries in this field. Current patents referring to CSCs (70+ by Dec 2007) are also presented.

"Cancer Stem Cells -- Emerging Therapeutic, Diagnostic and Market Opportunities (2008)" is available in pdf format from Piribo. For more information, go to:

http://www.piribo.com/publications/diseases_conditions/cancer/cancer_stem_cells.html

Piribo product ID: BPR001

About Piribo.

Piribo (http:www.piribo.com) is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK's largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

###